Intelligent Bio Solutions Closes $10.1 Million Private Placement to Advance Non-Invasive Testing Solutions

Photo of author
Written By Faith Boluwatife

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a pioneering medical technology company specializing in rapid and non-invasive testing solutions, has successfully completed a private placement priced at-the-market under Nasdaq rules. 

This announcement signifies a significant milestone for the company as it secures funding to advance its innovative Intelligent Fingerprinting Drug Screening System and expand its market presence. 

This analysis will provide an overview of the private placement, its implications for Intelligent Bio Solutions, and the company’s strategic outlook.

Private Placement Details

The private placement involved the issuance of 2,223,333 shares of common stock (or pre-funded warrants), Series H-1 warrants, and Series H-2 warrants, at a combined purchase price of $4.55 per share (or pre-funded warrant). 

Credits: DepositPhotos

The gross proceeds amounted to approximately $10.1 million, before deducting placement agent fees and other offering expenses. The Series H-1 and H-2 warrants have exercise prices of $4.55 per share and are immediately exercisable upon issuance. 

The Series H-1 warrants have a term of eighteen months, while the Series H-2 warrants have a term of five years, with a provision for accelerated exercise following FDA clearance of the Intelligent Fingerprinting Drug Screening System.

Read More: Hello Group Inc.’s Long-Term Performance Show’s Potential: Will The Stock Rally Continue?

Strategic Utilization of Proceeds

Harry Simeonidis, President and CEO of Intelligent Bio Solutions, expressed gratitude to the new healthcare-focused investors and outlined the company’s plans for utilizing the proceeds. 

The funds will be allocated towards general corporate purposes, including advancing clinical trials for the Intelligent Fingerprinting Drug Screening System, as well as market expansion initiatives. This strategic allocation of capital underscores Intelligent Bio Solutions’ commitment to innovation and growth in the rapidly evolving medical technology landscape.

Exclusive Placement Agent

Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the private placement, highlighting Intelligent Bio Solutions’ ability to attract reputable partners to support its financing initiatives. 

The involvement of Ladenburg Thalmann underscores investor confidence in the company’s vision and potential for disruptive impact in the healthcare sector.

Also Read: Is Golar LNG a Buy After its Most Recent Earnings Beat?

Regulatory Considerations

The offer and sale of securities were conducted in compliance with regulatory requirements, including those stipulated by the Securities Act of 1933 and applicable state securities laws. 

Intelligent Bio Solutions will file an initial registration statement with the SEC to facilitate the resale of shares issued to investors, demonstrating transparency and adherence to regulatory standards.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is at the forefront of medical technology innovation, specializing in rapid and non-invasive testing solutions. 

The company’s Intelligent Fingerprinting Drug Screening System offers a revolutionary approach to portable testing through fingerprint sweat analysis. 

With applications in workplace drug screening and beyond, Intelligent Bio Solutions aims to provide cost-effective and hygienic testing solutions to diverse customer segments, including safety-critical industries and drug treatment organizations.

Advancing Innovation to Drive Growth 

The successful completion of the $10.1 million private placement underscores Intelligent Bio Solutions’ commitment to advancing innovative testing solutions and driving market expansion. 

Credits: DepositPhotos

With a strong financial foundation and strategic allocation of proceeds, the company is well-positioned to capitalize on emerging opportunities in the medical technology sector. Investors and stakeholders can anticipate continued progress and transformative developments as Intelligent Bio Solutions continues to revolutionize non-invasive testing methodologies.

Read Next: Aptorum Group Faces Stock Decline After Announcing Direct Offering


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.